PLAU and familial pancreatic carcinoma: b) reduction of uPA production by cancer cells, thus preventing further HGF activation (thus inhibiting the positive feedback loop).c) blockade of stemness in cancer cells (given that c-MET is recognized to be a stem cell marker in pancreatic cancer [30, 43]).